Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Deffered Revenue (2016 - 2025)

Dare Bioscience's Non-Current Deffered Revenue history spans 8 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $1.0 million, changed 0.0%, while the annual FY2024 figure was $1.0 million, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue reached $1.0 million in Q3 2025 per DARE's latest filing, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q2 2023 to a low of $1.0 million in Q1 2021.
  • Average Non-Current Deffered Revenue over 5 years is $1.0 million, with a median of $1.0 million recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: rose 20.52% in 2023, then fell 17.03% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Non-Current Deffered Revenue are $1.0 million (Q3 2025), $1.0 million (Q2 2025), and $1.0 million (Q1 2025).